FOXM1 and cancer: The results showed that intracellular paclitaxel concentrations were significantly increased following FOXM1 downregulation by both shRNA and Siomycin A, indicating the potential of Siomycin A in sensitizing chemo-resistant cancer cells to paclitaxel.